论文部分内容阅读
基于胰升血糖素样肽-1(GLP-1)而开发的多种药品,具有促进胰岛素释放、延缓胃排空和降低食欲等生理作用,在降低血糖的同时不会增加体质量,且可在改善胰岛细胞功能和增加胰岛素敏感性方面发挥作用,为糖尿病治疗提供新途径。1 GLP-1分布GLP-1通过与细胞表面特异性受体结合而发挥作用。GLP-1受体在胰腺中分布于β细胞、α细胞、δ细胞,此外,还广泛分布于心脏、中枢神经系统、肾、肺、胃、肠、垂体以及腹部迷
A variety of drugs developed based on glucagon-like peptide-1 (GLP-1) have the physiological effects of promoting insulin release, delaying gastric emptying, and reducing appetite and do not increase body weight while lowering blood glucose, Play a role in improving islet cell function and increasing insulin sensitivity, providing a new way for the treatment of diabetes. 1 GLP-1 Distribution GLP-1 functions by binding to cell-surface-specific receptors. The GLP-1 receptor is distributed in the pancreas in beta cells, alpha cells, and delta cells and is also widely distributed in the heart, central nervous system, kidney, lung, stomach, intestine, pituitary, and abdomen